DiagnoCure Licenses Multi-Marker CRC Staging Test to China's Shuwen Biotech | GenomeWeb

NEW YORK (GenomeWeb) — Canadian cancer diagnostics firm DiagnoCure said this week that it has granted an exclusive license to China's Shuwen Biotech to commercialize DiagnoCure's Previstage GCC colorectal cancer staging test in China, Hong Kong, and Taiwan.

The agreement includes a "clear commercial development plan in which both corporations are committed to close collaboration that is expected to lead to the expansion of the clinical use of the test," DiagnoCure said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.